These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

929 related items for PubMed ID: 28196724

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Persistence with prescribed antimuscarinic therapy for overactive bladder: a UK experience.
    Wagg A, Compion G, Fahey A, Siddiqui E.
    BJU Int; 2012 Dec; 110(11):1767-74. PubMed ID: 22409769
    [Abstract] [Full Text] [Related]

  • 4. Cost-Effectiveness of Mirabegron Compared with Antimuscarinic Agents for the Treatment of Adults with Overactive Bladder in the United Kingdom.
    Nazir J, Maman K, Neine ME, Briquet B, Odeyemi IA, Hakimi Z, Garnham A, Aballéa S.
    Value Health; 2015 Sep; 18(6):783-90. PubMed ID: 26409605
    [Abstract] [Full Text] [Related]

  • 5. Persistence and adherence with mirabegron vs antimuscarinics in overactive bladder: Retrospective analysis of a UK General Practice prescription database.
    Wagg AS, Foley S, Peters J, Nazir J, Kool-Houweling L, Scrine L.
    Int J Clin Pract; 2017 Oct; 71(10):. PubMed ID: 28906080
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Oral pharmacotherapy for overactive bladder in older patients: mirabegron as a potential alternative to antimuscarinics.
    Wagg A, Nitti VW, Kelleher C, Castro-Diaz D, Siddiqui E, Berner T.
    Curr Med Res Opin; 2016 Oct; 32(4):621-38. PubMed ID: 26828974
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Safety and Efficacy of Mirabegron: Analysis of a Large Integrated Clinical Trial Database of Patients with Overactive Bladder Receiving Mirabegron, Antimuscarinics, or Placebo.
    Chapple CR, Cruz F, Cardozo L, Staskin D, Herschorn S, Choudhury N, Stoelzel M, Heesakkers J, Siddiqui E.
    Eur Urol; 2020 Jan; 77(1):119-128. PubMed ID: 31635815
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Safety, efficacy, and persistence of long-term mirabegron treatment for overactive bladder in the daily clinical setting: Interim (1-year) report from a Japanese post-marketing surveillance study.
    Kato D, Tabuchi H, Uno S.
    Low Urin Tract Symptoms; 2019 Jan; 11(1):14-23. PubMed ID: 28762672
    [Abstract] [Full Text] [Related]

  • 14. Treatment Patterns with Mirabegron and Antimuscarinics for Overactive Bladder: A Prospective, Registry Study in Taiwan and South Korea (FAITH).
    Oh SJ, Cho ST, Kuo HC, Chou EC, Hsu YC, Lee KS, Hadi F, Song Y, Sumarsono B.
    Adv Ther; 2024 Apr; 41(4):1652-1671. PubMed ID: 38430402
    [Abstract] [Full Text] [Related]

  • 15. Real-world persistence and adherence to oral antimuscarinics and mirabegron in patients with overactive bladder (OAB): a systematic literature review.
    Yeowell G, Smith P, Nazir J, Hakimi Z, Siddiqui E, Fatoye F.
    BMJ Open; 2018 Nov 21; 8(11):e021889. PubMed ID: 30467131
    [Abstract] [Full Text] [Related]

  • 16. Persistence and adherence to overactive bladder medications in Japan: A large nationwide real-world analysis.
    Kato D, Uno S, Van Schyndle J, Fan A, Kimura T.
    Int J Urol; 2017 Oct 21; 24(10):757-764. PubMed ID: 28833621
    [Abstract] [Full Text] [Related]

  • 17. Comparative efficacy and safety of medical treatments for the management of overactive bladder: a systematic literature review and mixed treatment comparison.
    Maman K, Aballea S, Nazir J, Desroziers K, Neine ME, Siddiqui E, Odeyemi I, Hakimi Z.
    Eur Urol; 2014 Apr 21; 65(4):755-65. PubMed ID: 24275310
    [Abstract] [Full Text] [Related]

  • 18. Results of a randomized, double-blind, parallel-group, placebo- and active-controlled, multicenter study of mirabegron, a β3-adrenoceptor agonist, in patients with overactive bladder in Asia.
    Kuo HC, Lee KS, Na Y, Sood R, Nakaji S, Kubota Y, Kuroishi K.
    Neurourol Urodyn; 2015 Sep 21; 34(7):685-92. PubMed ID: 25130281
    [Abstract] [Full Text] [Related]

  • 19. Estimated Budget Impact of Increased Use of Mirabegron, A Novel Treatment for Overactive Bladder.
    Perk S, Wielage RC, Campbell NL, Klein TM, Perkins A, Posta LM, Yuran T, Klein RW, Ng DB.
    J Manag Care Spec Pharm; 2016 Sep 21; 22(9):1072-84. PubMed ID: 27579830
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 47.